{"id":"75ea35115f05","type":"article","url":"https://hartvaat.nl/2019/07/01/kosteneffectiviteit-van-statines-en-ezetimibe-bij-chronische-nierziekte/","title":"Kosteneffectiviteit van statines en ezetimibe bij chronische nierziekte","title_en":"Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.","category":"cholesterol","category_label":"Cholesterol","professions":["cardioloog","internist"],"tags":["acuut-hartfalen","anemie-ckd","chronische-nierziekte","cystatine-c","dyslipidemie","ezetimibe","figaro-dkd","ijzertekort","niertransplantatie","niet-statine-therapie","rosuvastatine","statines","vrouwen"],"journal":"Kidney international","doi":"10.1016/j.kint.2019.01.028","source_url":"https://doi.org/10.1016/j.kint.2019.01.028","authors":["Iryna Schlackow","Seamus Kent","William Herrington","Jonathan Emberson","Richard Haynes","Christina Reith","Rory Collins","Martin J Landray","Alastair Gray","Colin Baigent","Borislava Mihaylova"],"significance":6,"published":"2019-07-01","source_date":"2019-07-01","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/lipidenmedicatie-bij-ckd/","https://hartvaat.nl/kennis/preventie/preventie-bij-ckd/"],"congress":"","summary_en":"This cost-effectiveness analysis evaluated lipid-lowering with statins and ezetimibe in CKD, comparing different treatment intensities to determine the economically optimal lipid management strategy in kidney disease.","created":"2026-07-03T10:28:01Z","updated":"2026-07-03T13:27:13Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Kosteneffectiviteitsanalyse van lipidenverlaging met statines en ezetimibe bij CKD-patiënten.","abstract_original":"Statin-based treatments reduce cardiovascular disease (CVD) risk in patients with non-dialysis chronic kidney disease (CKD), but it is unclear which regimen is the most cost-effective. We used the Study of Heart and Renal Protection (SHARP) CKD-CVD policy model to evaluate the effect of statins and ezetimibe on quality-adjusted life years (QALYs) and health care costs in the United States (US) and the United Kingdom (UK). Net costs below $100,000/QALY (US) or £20,000/QALY (UK) were considered cost-effective. We investigated statin regimens with or without ezetimibe 10 mg. Treatment effects on cardiovascular risk were estimated per 1-mmol/L reduction in low-density lipoprotein (LDL) cholesterol as reported in the Cholesterol Treatment Trialists' Collaboration meta-analysis, and reductions in LDL cholesterol were estimated for each statin/ezetimibe regimen. In the US, atorvastatin 40 mg ($0.103/day as of January 2019) increased life expectancy by 0.23 to 0.31 QALYs in non-dialysis patients with stages 3B to 5 CKD, at a net cost of $20,300 to $78,200/QALY. Adding ezetimibe 10 mg ($0.203/day) increased life expectancy by an additional 0.05 to 0.07 QALYs, at a net cost of $43,600 to $91,500/QALY. The cost-effectiveness findings and policy implications in the UK were similar. In summary, in patients with non-dialysis-dependent CKD, the evidence suggests that statin/ezetimibe combination therapy is a cost-effective treatment to reduce the risk of CVD."}